The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density
Abstract
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone resorption in preclinical and phase I studies. A 1-year dose-finding trial with a 1-year extension on the same treatment assignment was performed in postmenopausal women with low bone mineral density (BMD) to evaluate the safety and efficacy of weekly doses of placebo or 3, 10, 25, or 50 mg of odanacatib on BMD and biomarkers of skeletal remodeling. Women with BMD T-scores of −2.0 or less but not less than −3.5 at the lumbar spine or femoral sites were randomly assigned to receive placebo or one of four doses of odanacatib; all received vitamin D with calcium supplementation as needed. The primary endpoint was percentage change from baseline lumbar spine BMD. Other endpoints included percentage change in BMD at hip and forearm sites, as well as changes in biomarkers of skeletal remodeling. Twenty-four months of treatment produced progressive dose-related increases in BMD. With the 50-mg dose of odanacatib, lumbar spine and total-hip BMD increased 5.5% and 3.2%, respectively, whereas BMD at these sites was essentially unchanged with placebo (−0.2% and −0.9%). Biochemical markers of bone turnover exhibited dose-related changes. The safety and tolerability of odanacatib generally were similar to those of placebo, with no dose-related trends in any adverse experiences. In summary, 2 years of weekly odanacatib treatment was generally well-tolerated and increased lumbar spine and total-hip BMD in a dose-related manner in postmenopausal women with low BMD. © 2010 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L. T., Falgueyret, J.-P., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 477
Garnero, P., Ferreras, M., Karsdal, M., Nicamhlaoibh, R., Risteli, J., Borel, O., Qvist, P., Delmas, P., Foged, N., & Delaissé, J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.859 · Cited by 472
Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Vasiljeva, O., Reinheckel, T., Peters, C., Turk, D., Turk, V., & Turk, B. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780162962 · Cited by 450
Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption
Halleen, J. M., Alatalo, S. L., Suominen, H., Cheng, S., Janckila, A. J., & Väänänen, H. K. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1337 · Cited by 415
The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics
YASUDA, Y., KALETA, J., & BROMME, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.013 · Cited by 300
Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?
Karsdal, M. A., Martin, T. J., Bollerslev, J., Christiansen, C., & Henriksen, K. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070109 · Cited by 242
Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure
Recker, R. R., Delmas, P. D., Halse, J., Reid, I. R., Boonen, S., García-Hernandez, P. A., Supronik, J., Lewiecki, E. M., Ochoa, L., Miller, P., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070906 · Cited by 225
Self-citationUusi-Rasi, K., Kannus, P., Cheng, S., Sievänen, H., Pasanen, M., Heinonen, A., Nenonen, A., Halleen, J., Fuerst, T., Genant, H., et al. (2003) · Bone · doi:10.1016/s8756-3282(03)00082-6 · Cited by 187
Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy
Stoch, S., & Wagner, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100450 · Cited by 178
Cited by
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Self-citationPrevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
A comprehensive overview on osteoporosis and its risk factors
Pouresmaeili, F., Kamali Dehghan, B., Kamarehei, M., & Yong Meng, G. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s138000 · Cited by 597
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Bone metastasis: the importance of the neighbourhood
Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.44 · Cited by 479
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Karsdal, M. A., Michaelis, M., Ladel, C., Siebuhr, A. S., Bihlet, A. R., Andersen, J. R., Guehring, H., Christiansen, C., Bay-Jensen, A. C., & Kraus, V. B. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.07.017 · Cited by 381
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
for the National Bone Health Alliance Bone Turnover Marker Project, Szulc, P., Naylor, K., Hoyle, N. R., Eastell, R., & Leary, E. T. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4082-4 · Cited by 327
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
Costa, A. G., Cusano, N. E., Silva, B. C., Cremers, S., & Bilezikian, J. P. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.77 · Cited by 287
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned
Drake, M. T., Clarke, B. L., Oursler, M. J., & Khosla, S. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1114 · Cited by 266
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
McClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Kiel, D. P., Cavallari, I., Bonaca, M. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30346-8 · Cited by 169
Self-citationCoupling factors involved in preserving bone balance
Kim, B.-J., & Koh, J.-M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2981-y · Cited by 111
Stone, J. A., McCrea, J. B., Witter, R., Zajic, S., & Stoch, S. A. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13869 · Cited by 66
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63
Future directions for new medical entities in osteoporosis
Ferrari, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.002 · Cited by 34
Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., Disteche, S., & Bruyere, O. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0179-z · Cited by 29
Metadata
- Authors
- Bone, H. G., McClung, M. R., Roux, C., Recker, R. R., Eisman, J. A., Verbruggen, N., Hustad, C. M., DaSilva, C., Santora, A. C., & Ince, B. A.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-30
- Volume
- 25
- Issue
- 5
- Pages
- 937-947
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2028917977
- Cited by
- 335
- References
- 22
- FWCI
- 35.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.